Takeda has acquired molecule specialist Intellikine through its Takeda America Holdings subsidiary, a move that will add two oncology candidates to its drug pipeline.
Takeda expects that the transaction will be finalised in January 2012 under an agreement worth $190m upfront and up to $120m in additional potential clinical development milestone payments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Intellikine’s most advanced drug candidate, INK128, a novel mTORC1/2 inhibitor, has generated encouraging data in multiple Phase I studies. It is expected to enter Phase II studies in 2012.
INK1117, a novel and selective inhibitor of the PI3Ka isoform, entered human clinical testing in September 2011.
Intellikine CEO Troy Wilson said that Intellikine has advanced three programmes against the PI3K/mTOR pathway into human clinical testing in just four years
"Together with Millennium and Takeda, we can bring the resources and expertise necessary to enable our drug candidates to reach their full potential in the treatment of patients with cancer," said Wilson.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTakeda does not expect to revise earnings guidance for its 2011 fiscal year in connection with this acquisition.
